Podcast

Bringing Together the Lung Cancer Community

Author(s):

Kristie L. Kahl

In this episode of the “CURE Talks Cancer” podcast, we looked back on CURE’s Lung Cancer Heroes event and recognized each winner that helps bring together the lung cancer community to raise awareness.

On October 15th, CURE® recognized five individuals for their contributions to the lung cancer space and raising awareness to end the stigma, inform, connect, and empower anyone who has been impacted by lung cancer.

During the inaugural virtual event, four individuals — two physicians, a nurse and a patient turned advocate — were awarded for their contributions to the lung cancer community. The program also recognized one Lifetime Achievement award winner.

lung cancer, Takeda, heroes, patients, community

In this episode of the “CURE Talks Cancer” podcast, we spoke with Bonnie J. Addario, Carolyn Baggett, Dr. Jennifer Garst, Dr. Fred Hirsh and Deborah Pickworth about their contributions and why bringing the lung cancer community is vital in raising awareness around the disease.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
a man and a woman in front of a dark blue background for CURE Speaking Out
How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment
a man and a woman in front of a dark blue background for CURE Speaking Out
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
a man and a woman in front of a dark blue background for CURE Speaking Out
What the FDA Approval of Bizengri Means for Patients With NRG1-Positive NSCLC
a man and a woman in front of a dark blue background for CURE Speaking Out
What’s On the Horizon for Small Cell Lung Cancer Research?
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Image of a man in a suit.
Monitoring Treatment With Different Types of Biopsies in Lung Cancer
Image of man with black hair.
Resistance Mechanisms May Steer Therapy Sequences in EGFR-Mutated Lung Cancer
Image of man with gray hair.
Rybrevant Plus Chemotherapy May Improve PFS for Relapsed EGFR Lung Cancer
Image of Dr. Minesh Mehta at ASCO 2024.
Tumor Treating Fields for Brain Metastases in Lung Cancer Boost Quality of Life With Some Trade-Offs
Related Content
Illustration of lungs.
April 1st 2025

Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC

Alex Biese
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in EGFR+ advanced or metastatic NSCLC: © SciePro - stock.adobe.com
March 31st 2025

First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer

Ryan Scott
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
CAN-2409 elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer: © steph_photographis - stock.adobe.com
March 27th 2025

CAN-2409 Elicits Survival Responses In NSCLC

Alex Biese
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.
Image of cancer vaccine.
March 25th 2025

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

Spencer Feldman
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.